Home

Pathogen Capture Technology

Human pathogens such as viruses, bacteria and fungi, bind to proteins and sugar chains on our cell surfaces to establish an infection.

Aquila’s proprietary PCT uses biomolecules that mimic these glycoproteins to bind to the protein spikes on pathogens, capturing and neutralising them. These strong covalent bonds are similar to Velcro®, a mechanism from which they cannot escape.

This technology is already being applied in the ABD Device and ProShield Mask Spray and our R&D teams continue to develop new products and applications.

01

ABD DEVICE

The ABD wipe (Anti Bioagent Decontamination Device) uses pathogen capture technology to remove 99.99% of pathogens, including SARS-CoV-2 (COVID-19), from human skin. It can be applied safely and comfortably to sensitive areas like around the eyes, nose and mouth.
02

USA FDA

The product is a US FDA registered Class I medical device that comes in the form of a decontamination wipe.
03

PROSHIELD MASK SPRAY

ProShield Mask Spray™ converts simple cloth masks into a highly protective face coverings while helping the environment. ProShield Mask Spray contains no alcohol or toxic chemicals. Acting as an invisible shield on the reusable face mask, it prevents pathogens from entering the human airways.

Inspired by Nature. Excellence in Science

Aquila Bioscience is an innovative R&D company aiming to deliver disruptive technologies and sustainable solutions in carbohydrate based biology, and its applications in pathogen management.
Aquila Bioscience is heavily invested in scientific research and is busy discussing, presenting and writing about developments in green chemistry and glycoscience.
Carbohydrates (also called glycans) are universally present on every cell and are essential for cell-cell communication. Aquila Bioscience is at the forefront of applying glycoscience.
Our mission is to protect the world’s health through developing technologically advanced and environmentally friendly products using nature based solutions.
Aquila Bioscience creates innovative products free from alcohol, biocides and toxic chemicals and as so, do not cause skin irritation or destroy skin cells.
The team at Aquila Bioscience strives to make products 99.99% SARS-Cov-2 available that are the best on the market for safely protecting humans against ever-changing pathogens.

15

R&D Staff

200 M2

BioInnovation Space

3.5 m

Research Funding

99 .99%

Effective Against SARS-CoV-2

Our products are shipped to clients globally.

MEDICAL RESEARCH 90%
BIOTECHNOLOGY 80%
Czech-University-of-Defence_new_logo
EU_co-funded_logo_cropped

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 959436

Pathogen Capture Technology

Human pathogens such as viruses, bacteria and fungi, bind to proteins and sugar chains on our cell surfaces to establish an infection.

Aquila’s proprietary PCT uses biomolecules that mimic these glycoproteins to bind to the protein spikes on pathogens, capturing and neutralising them. These strong covalent bonds are similar to Velcro®, a mechanism from which they cannot escape.

This technology is already being applied in the ABD Device and ProShield Mask Spray and our R&D teams continue to develop new products and applications.

01

ABD DEVICE

The ABD wipe (Anti Bioagent Decontamination Device) uses pathogen capture technology to remove 99.99% of pathogens, including SARS-CoV-2 (COVID-19), from human skin. It can be applied safely and comfortably to sensitive areas like around the eyes, nose and mouth.
02

USA FDA

The product is a US FDA registered Class I medical device that comes in the form of a decontamination wipe.
03

PROSHIELD MASK SPRAY

ProShield Mask Spray™ converts simple cloth masks into a highly protective face coverings while helping the environment. ProShield Mask Spray contains no alcohol or toxic chemicals. Acting as an invisible shield on the reusable face mask, it prevents pathogens from entering the human airways.

Inspired by Nature. Excellence in Science

Aquila Bioscience is an innovative R&D company aiming to deliver disruptive technologies and sustainable solutions in carbohydrate based biology, and its applications in pathogen management.
Aquila Bioscience is heavily invested in scientific research and is busy discussing, presenting and writing about developments in green chemistry and glycoscience.
Carbohydrates (also called glycans) are universally present on every cell and are essential for cell-cell communication. Aquila Bioscience is at the forefront of applying glycoscience.
Our mission is to protect the world’s health through developing technologically advanced and environmentally friendly products using nature based solutions.
Aquila Bioscience creates innovative products free from alcohol, biocides and toxic chemicals and as so, do not cause skin irritation or destroy skin cells.
The team at Aquila Bioscience strives to make products 99.99% SARS-Cov-2 available that are the best on the market for safely protecting humans against ever-changing pathogens.

15

R&D Staff

200 M2

BioInnovation Space

3.5 m

Research Funding

99 .99%

Effective Against SARS-CoV-2

Our products are shipped to clients globally.

MEDICAL RESEARCH 90%
BIOTECHNOLOGY 80%
Czech-University-of-Defence_new_logo
EU_co-funded_logo_cropped

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 959436